Analyte monitoring and automatic drug delivery system
阅读说明:本技术 一种分析物监测与自动给药系统 (Analyte monitoring and automatic drug delivery system ) 是由 张艳 于 2018-09-05 设计创作,主要内容包括:本发明提供一种分析物监测与自动给药系统,包括:检注装置、临时存储装置和主调控装置,检注装置与临时存储装置或主调控装置可拆卸连接;临时存储装置和主调控装置可拆卸连接;检注装置包括至少两个检测部件、至少两个注射部件和基片,各检测部件均用于检测分析物中的分析对象,各注射部件均用于注射药物。临时存储装置包括临时数据存储装置和临时药物存储装置,主调控装置包括第二储药部件和注射泵,临时存储装置和主调控装置可拆卸连接。本发明提供的分析物监测与自动给药系统,使用方便、对患者产生疼痛感以及生产成本较小、体积较小。(The invention provides an analyte monitoring and automatic drug delivery system, which comprises an injection detection device, a temporary storage device and a main control device, wherein the injection detection device is detachably connected with the temporary storage device or the main control device; the temporary storage device is detachably connected with the main regulation and control device; the injection detecting device comprises at least two detecting parts, at least two injection parts and a substrate, wherein each detecting part is used for detecting an analysis object in an analyte, and each injection part is used for injecting a medicine. The temporary storage device comprises a temporary data storage device and a temporary medicine storage device, the main control device comprises a second medicine storage part and an injection pump, and the temporary storage device is detachably connected with the main control device. The analyte monitoring and automatic drug delivery system provided by the invention is convenient to use, generates pain to patients, and has the advantages of low production cost and small volume.)
1. An analyte monitoring and automatic drug delivery system is characterized by comprising a filling device, a temporary storage device and a main control device,
the injection checking device is detachably connected with the temporary storage device or the main regulation and control device;
the temporary storage device is detachably connected with the main control device;
the injection device includes a substrate and at least two detection parts, at least two injection parts, each of the detection parts for detecting an analysis object in an analyte, each of the injection parts for injecting a medicine, each of the detection parts and each of the injection parts being formed as a needle-shaped member having one end attached to one side surface of the substrate and having a fluid passage formed therein, and the other end of each of the detection parts and each of the injection parts being formed as a tip; the depth of each detection part and each injection part inserted into the interstitial tissue of a patient is between 0.3mm and 5 mm;
the temporary storage device comprises a temporary data storage device and a temporary medicine storage device;
the temporary data storage device is used for temporarily storing the detection result of each detection component; sending the stored detection result to the main control device;
the temporary drug storage device comprises a first drug storage component and a piston type pushing member;
the main control device comprises a second medicine storage part and an injection pump;
the base sheet further comprises a drug dispensing passage through which the first drug storage part or the second drug storage part communicates with each of the injection parts.
2. The analyte monitoring and automatic drug delivery system of claim 1, wherein the priming device is removably connected to the temporary storage device by a first connector;
the injection detecting device is detachably connected with the main regulating device through a second connecting piece;
the temporary storage device and the main control device are detachably connected through a third connecting piece.
3. The analyte monitoring and automatic drug delivery system of claim 2, wherein the master control device further comprises a processor and a controller,
the processor analyzes and processes the detection result of each detection component to obtain a processing numerical value corresponding to the detection result of each detection component; the processor is also used for comparing and calculating the processing value corresponding to each detection component to obtain an instant monitoring result; the processor is further configured to calculate a total injection volume of the drug;
the controller is used for controlling the injection device and the processor, and the controller is electrically connected with the processor.
4. The automatic drug injection device of claim 3, wherein:
the processor calculates the total injection amount of the medicine according to the weight, the waist-hip ratio, the content of triglyceride in blood, the blood glucose monitoring value before meals and the blood glucose change trend in three days of a patient; and is
The processor calculates a total injection volume of the drug according to the following formula:
wherein:
L1: a total injected amount (u) of the drug calculated by the processor;
k: body weight (Kg) of the subject;
y: waist-to-hip ratio of the subject;
x: triglyceride (mmol/L) content in blood of the subject of injection, wherein:
triglyceride content below 1.7: x is 1;
a triglyceride content greater than 1.7 and below 2.5: x is 1.1;
a triglyceride content greater than 2.5 and below 5: x is 1.2;
a triglyceride content of greater than 5 and below 10: x is 1.3;
a triglyceride content of greater than 2.5 and less than 5: x is 1.4;
a: mean blood glucose (mmol/L) before a single day meal of the subject;
a: pre-prandial blood glucose trend within three days of the subject, wherein:
when the pre-prandial blood glucose change for the injected subjects was generally within ± 5% of the initial measurement within three days: a is 1;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased within 10% compared with the blood sugar minimum value: a is 1.1;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased by more than 10% and within 20% compared with the blood sugar minimum value: a is 1.2;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased by more than 20% and within 30% compared with the blood sugar minimum value: a is 1.3;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased by more than 30% and within 40% compared with the blood sugar minimum value: a is 1.4;
when the change of blood sugar before meals in three days of the injection subject generally shows an ascending trend, and the blood sugar maximum value is increased by more than 40 percent compared with the blood sugar minimum value: a is 1.5; and is
When the change of blood sugar before meals in three days of the injection subject generally has a descending trend, and the blood sugar minimum value is reduced by 10 percent compared with the blood sugar maximum value: a is 0.9;
when the change of blood sugar before meals in three days of the injection subject is generally in a descending trend, and the blood sugar minimum value is descended by more than 10% and within 20% compared with the blood sugar maximum value: a is 0.8;
when the change of blood sugar before meals in three days of the injection subject is generally in a descending trend, and the blood sugar minimum value is reduced by more than 20% and within 30% compared with the blood sugar maximum value: a is 0.7;
when the change of blood sugar before meals in three days of the injection subject is generally in a descending trend, and the blood sugar minimum value is reduced by less than 40% compared with the blood sugar maximum value: and a is 0.6.
5. The automatic drug injection device of claim 3, wherein:
the processor calculates the total injection amount of the medicine according to the weight, the waist-hip ratio, the triglyceride content in blood, the pre-meal blood sugar monitoring value, the post-meal blood sugar monitoring value and the blood sugar change trend in three days of the patient; and is
The processor calculates a total injection volume of the drug according to the following formula:
wherein:
L2: a total injected amount (u) of the drug calculated by the processor;
k: body weight (Kg) of the subject;
y: waist-to-hip ratio of the subject;
x: triglyceride (mmol/L) content in blood of the subject of injection, wherein:
triglyceride content below 1.7: x is 1;
a triglyceride content greater than 1.7 and below 2.5: x is 1.1;
a triglyceride content greater than 2.5 and below 5: x is 1.2;
a triglyceride content of greater than 5 and below 10: x is 1.3;
a triglyceride content of greater than 2.5 and less than 5: x is 1.4;
a: mean blood glucose (mmol/L) before a single day meal of the subject;
a: pre-prandial blood glucose trend within three days of the subject, wherein:
when the pre-prandial blood glucose change for the injected subjects was generally within ± 5% of the initial measurement within three days: a is 1;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased within 10% compared with the blood sugar minimum value: a is 1.1;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased by more than 10% and within 20% compared with the blood sugar minimum value: a is 1.2;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased by more than 20% and within 30% compared with the blood sugar minimum value: a is 1.3;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased by more than 30% and within 40% compared with the blood sugar minimum value: a is 1.4;
when the change of blood sugar before meals in three days of the injection subject generally shows an ascending trend, and the blood sugar maximum value is increased by more than 40 percent compared with the blood sugar minimum value: a is 1.5; and is
When the change of blood sugar before meals in three days of the injection subject generally has a descending trend, and the blood sugar minimum value is reduced by 10 percent compared with the blood sugar maximum value: a is 0.9;
when the change of blood sugar before meals in three days of the injection subject is generally in a descending trend, and the blood sugar minimum value is descended by more than 10% and within 20% compared with the blood sugar maximum value: a is 0.8;
when the change of blood sugar before meals in three days of the injection subject is generally in a descending trend, and the blood sugar minimum value is reduced by more than 20% and within 30% compared with the blood sugar maximum value: a is 0.7;
when the change of blood sugar before meals in three days of the injection subject is generally in a descending trend, and the blood sugar minimum value is reduced by less than 40% compared with the blood sugar maximum value: a is 0.6; and
b: mean blood glucose (mmol/L) after a single day of injection of the subject;
b: a trend of postprandial blood glucose change within three days of the injected subject, wherein:
when the postprandial blood glucose change for the injected subjects was overall within ± 5% of the initial measurement within three days: a is 1;
when the blood sugar changes after three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased within 10% compared with the blood sugar minimum value: a is 1.1;
when the blood glucose changes after three days of the injection subject generally show an ascending trend, and the blood glucose maximum value is increased by more than 10% and within 20% compared with the blood glucose minimum value: a is 1.2;
when the blood glucose changes after three days of the injection subject generally show an ascending trend, and the blood glucose maximum value is increased by more than 20% and within 30% compared with the blood glucose minimum value: a is 1.3;
when the blood glucose changes after three days of the injection subject generally show an ascending trend, and the blood glucose maximum value is increased by more than 30% and within 40% compared with the blood glucose minimum value: a is 1.4;
when the blood glucose changes after three days of the injection subject generally show an ascending trend, and the blood glucose maximum value is increased by more than 40% compared with the blood glucose minimum value: a is 1.5; and is
When the blood sugar changes after three days of the injection subject are generally in a descending trend, and the blood sugar minimum value is reduced within 10% compared with the blood sugar maximum value: a is 0.9;
when the blood sugar changes after three days of the injection subject are generally in a descending trend, and the blood sugar minimum value is reduced by more than 10% and within 20% compared with the blood sugar maximum value: a is 0.8;
when the blood sugar changes after three days of the injection subject are generally in a descending trend, and the blood sugar minimum value is reduced by more than 20% and within 30% compared with the blood sugar maximum value: a is 0.7;
when the blood sugar changes after three days of the injection subject are generally in a descending trend, and the blood sugar minimum value is reduced within 40% compared with the blood sugar maximum value: a is 0.6; and is
Medicine injection amount L before breakfast21=L2×0.6;
Medicine injection L before supper22=L2×0.4。
6. The analyte monitoring and automatic drug delivery system of claim 3, wherein each of the detection components includes a working electrode and a reference electrode, the working electrode and the reference electrode being formed of different materials; an electron transfer layer is further arranged on the peripheral surface of each working electrode;
the processor is used for analyzing and processing the electric signals between the working electrode and the reference electrode in each detection part, so as to obtain corresponding processing values corresponding to each detection part.
7. The analyte monitoring and automatic drug delivery system of claim 6, wherein the master control device further comprises:
an input device through which a user may input personal information into the analyte monitoring and automatic injection system,
the processor may also accept user settings for the analyte monitoring and automatic drug delivery system.
The input device and the processor are electrically connected with the controller.
8. The analyte monitoring and automatic drug delivery system according to claim 7, wherein the master control device further comprises a prompt, and the processor is further configured to compare the processing values corresponding to the detection results of the detection components one by one, and compare the comparison values obtained after the one-by-one comparison with the preset monitoring threshold values; and the processor is further configured to compare the total injected amount of the drug to a medication threshold;
if the monitoring comparison value is larger than the monitoring threshold value and/or the total injection amount of the medicine is smaller than the medication threshold value, the prompting unit sends a prompting signal;
the prompter is electrically connected with the controller.
9. The analyte monitoring and automatic drug delivery system of claim 8, wherein the master control device further comprises:
a display for displaying the calculation result of the processor; and
a storage to store the computation results of the processor;
the display and the storage are respectively electrically connected with the controller.
10. The analyte monitoring and automatic drug delivery system of claim 9, wherein the master control device further comprises a transmitter for transmitting the processor's calculations and/or the calculations stored in the memory.
Technical Field
The present invention relates to a system for monitoring an analyte (e.g. glucose or blood ketones) and corresponding automatic drug delivery. More particularly, the present invention relates to a system for monitoring an analyte in a body using an electrochemical sensor and automatically administering a drug according to the monitoring result.
Background
Diabetes is a disease which is relatively common in our lives. It is well known that diabetes is a group of metabolic diseases characterized by hyperglycemia, which results from the inability of the pancreas to produce sufficient amounts of insulin, resulting in a reduced ability of the body to metabolize glucose, and thus, hyperglycemia (i.e., excess glucose present in the plasma). However, the medical level is not well developed at present, and a method for radically treating diabetes is not found, and only the dosage of hypoglycemic drugs can be adjusted by detecting the blood sugar of a diabetic patient through a detection method, so that the symptoms of the patient can be relieved.
In recent years, the mainstream monitoring method of blood sugar is fingertip blood sugar test, namely, a finger is pricked by a needle, and blood is collected and then reflected by test paper to the blood sugar level in a human body. The fingertip blood sugar test is simple and convenient, and is also accepted and applied by a large number of diabetics. However, in most cases, the measurement of blood glucose by fingertips of diabetic patients can be performed only at discrete time points, and the measurement method cannot show the variation trend of the blood glucose level of the patients in a period of time. Therefore, even the most active frequent blood glucose testers cannot find the frequent hyperglycemia or hypoglycemia, and it is difficult to observe the specific condition of blood glucose fluctuation. Especially at night. In addition, this method also does not facilitate recording of blood glucose data for the patient. Furthermore, the consistency of monitoring due to blood glucose levels varies greatly between individuals.
Further, over the years, although many devices have been developed for continuous or automated monitoring of analytes, such as glucose, in the blood stream or interstitial fluid. Many of these devices use electrochemical sensors. However, most of these devices require direct implantation into the patient's blood vessels or into the subcutaneous tissue, not only are they difficult to reproduce on a large scale or to produce inexpensively, but they are generally large, bulky, and/or inflexible, and many cannot be effectively utilized outside of a controlled medical facility (e.g., a hospital or doctor's office), which greatly limits the patient's freedom of movement.
The existing insulin injection device generally uses a common needle to inject insulin, and the needle has obvious pain when puncturing the skin. Meanwhile, if a patient wears the existing insulin injection device for a long time and needs the needle to be left in the skin for a long time, it is necessary to take sterilization measures from time to time, or wound infection due to sweat or the like may occur. In addition, because the needle needs to penetrate into the dermis for insulin injection, the needle is generally long, and the skin is easy to scar after long-term wearing.
In addition, because the existing insulin injection devices use a common needle head to inject the insulin, the injection position is concentrated, subcutaneous induration is easy to generate at the injection position, and discomfort is brought to patients. Further, the concentration of the injection site tends to slow the absorption of insulin, resulting in poor therapeutic effect.
Disclosure of Invention
The invention aims to provide an analyte monitoring and automatic drug delivery system, which can solve the problems of inconvenient use, pain feeling to patients, higher production cost, larger volume and the like of the analyte monitoring and automatic drug delivery system in the prior art, and further solve the problems of inconvenient use, pain feeling to patients, slow drug absorption, poor treatment effect and the like of a drug injection device in the prior art.
In order to solve the problems, the invention provides an analyte monitoring and automatic drug delivery system, which comprises an analyte monitoring and automatic drug delivery system and is characterized by comprising a filling device, a temporary storage device and a main control device,
the injection detection device is detachably connected with the temporary storage device or the main regulation and control device;
the temporary storage device is detachably connected with the main regulation and control device;
the injection detecting device includes at least two detecting parts, at least two injection parts and a substrate, each detecting part is used for detecting an analysis object in an analyte, each injection part is used for injecting a medicine, each detecting part and each injection part are formed into a needle-shaped member with one end attached to one side surface of the substrate and a fluid channel formed inside, and the other end of each detecting part and each injection part is formed into a tip; the depth of each detection component and each injection component inserted into the interstitial tissue of a patient is between 0.3mm and 5 mm;
the temporary storage device comprises a temporary data storage device and a temporary medicine storage device;
the temporary data storage device is used for temporarily storing the detection results of all the detection components; sending the stored detection result to a main control device;
the temporary drug storage device comprises a first drug storage part and a piston type pushing piece;
the main control device comprises a second medicine storage part and an injection pump;
the substrate further comprises a medicine distribution passage, and the first medicine storage part or the second medicine storage part is communicated with each injection part through the medicine distribution passage;
furthermore, the injection checking device is detachably connected with the temporary storage device through a first connecting piece;
the injection detection device is detachably connected with the main regulation device through a second connecting piece;
the temporary storage device and the main control device are detachably connected through a third connecting piece.
Furthermore, the main control device also comprises a processor and a controller, wherein the processor analyzes and processes the detection results of the detection parts to obtain processing numerical values corresponding to the detection results of the detection parts; the processor is also used for comparing and calculating the processing value corresponding to each detection component to obtain an instant monitoring result; the processor is also used for calculating the total injection quantity of the medicine; the controller is used for controlling the injection device and the processor.
Further, there is provided according to another aspect of the present invention an analyte monitoring and automatic drug delivery system, wherein: the processor calculates the total injection amount of the medicine according to the weight, the waist-hip ratio, the triglyceride content in blood, the blood sugar monitoring value before meals and the blood sugar change trend in three days of a patient; and is
The processor calculates the total injected amount of the drug according to the following formula:
wherein:
L1: a total injection amount (u) of the medicine calculated by the calculation unit;
k: body weight (Kg) of the subject;
y: waist-to-hip ratio of the subject;
x: triglyceride (mmol/L) content in blood of the subject of injection, wherein:
triglyceride content below 1.7: x is 1;
a triglyceride content greater than 1.7 and below 2.5: x is 1.1;
a triglyceride content greater than 2.5 and below 5: x is 1.2;
a triglyceride content of greater than 5 and below 10: x is 1.3;
a triglyceride content of greater than 2.5 and less than 5: x is 1.4;
a: mean blood glucose (mmol/L) before a single day meal of the subject;
a: pre-prandial blood glucose trend within three days of the subject, wherein:
when the pre-prandial blood glucose change for the injected subjects was generally within ± 5% of the initial measurement within three days: a is 1;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased within 10% compared with the blood sugar minimum value: a is 1.1;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased by more than 10% and within 20% compared with the blood sugar minimum value: a is 1.2;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased by more than 20% and within 30% compared with the blood sugar minimum value: a is 1.3;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased by more than 30% and within 40% compared with the blood sugar minimum value: a is 1.4;
when the change of blood sugar before meals in three days of the injection subject generally shows an ascending trend, and the blood sugar maximum value is increased by more than 40 percent compared with the blood sugar minimum value: a is 1.5; and is
When the change of blood sugar before meals in three days of the injection subject generally has a descending trend, and the blood sugar minimum value is reduced by 10 percent compared with the blood sugar maximum value: a is 0.9;
when the change of blood sugar before meals in three days of the injection subject is generally in a descending trend, and the blood sugar minimum value is descended by more than 10% and within 20% compared with the blood sugar maximum value: a is 0.8;
when the change of blood sugar before meals in three days of the injection subject is generally in a descending trend, and the blood sugar minimum value is reduced by more than 20% and within 30% compared with the blood sugar maximum value: a is 0.7;
when the change of blood sugar before meals in three days of the injection subject is generally in a descending trend, and the blood sugar minimum value is reduced by less than 40% compared with the blood sugar maximum value: and a is 0.6.
Further, there is provided according to another aspect of the present invention an analyte monitoring and automatic drug delivery system, wherein: the processor calculates the total injection amount of the medicine according to the weight, the waist-hip ratio, the triglyceride content in blood, the blood sugar before meal monitoring value, the blood sugar after meal monitoring value and the blood sugar change trend in three days of the patient; and is
The processor calculates the total injected amount of the drug according to the following formula:
wherein:
L2: a total injected amount (u) of the drug calculated by the processor;
k: body weight (Kg) of the subject;
y: waist-to-hip ratio of the subject;
x: triglyceride (mmol/L) content in blood of the subject of injection, wherein:
triglyceride content below 1.7: x is 1;
a triglyceride content greater than 1.7 and below 2.5: x is 1.1;
a triglyceride content greater than 2.5 and below 5: x is 1.2;
a triglyceride content of greater than 5 and below 10: x is 1.3;
a triglyceride content of greater than 2.5 and less than 5: x is 1.4;
a: mean blood glucose (mmol/L) before a single day meal of the subject;
a: pre-prandial blood glucose trend within three days of the subject, wherein:
when the pre-prandial blood glucose change for the injected subjects was generally within ± 5% of the initial measurement within three days: a is 1;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased within 10% compared with the blood sugar minimum value: a is 1.1;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased by more than 10% and within 20% compared with the blood sugar minimum value: a is 1.2;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased by more than 20% and within 30% compared with the blood sugar minimum value: a is 1.3;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased by more than 30% and within 40% compared with the blood sugar minimum value: a is 1.4;
when the change of blood sugar before meals in three days of the injection subject generally shows an ascending trend, and the blood sugar maximum value is increased by more than 40 percent compared with the blood sugar minimum value: a is 1.5; and is
When the change of blood sugar before meals in three days of the injection subject generally has a descending trend, and the blood sugar minimum value is reduced by 10 percent compared with the blood sugar maximum value: a is 0.9;
when the change of blood sugar before meals in three days of the injection subject is generally in a descending trend, and the blood sugar minimum value is descended by more than 10% and within 20% compared with the blood sugar maximum value: a is 0.8;
when the change of blood sugar before meals in three days of the injection subject is generally in a descending trend, and the blood sugar minimum value is reduced by more than 20% and within 30% compared with the blood sugar maximum value: a is 0.7;
when the change of blood sugar before meals in three days of the injection subject is generally in a descending trend, and the blood sugar minimum value is reduced by less than 40% compared with the blood sugar maximum value: a is 0.6; and
b: mean blood glucose (mmol/L) after a single day of injection of the subject;
b: a trend of postprandial blood glucose change within three days of the injected subject, wherein:
when the postprandial blood glucose change for the injected subjects was overall within ± 5% of the initial measurement within three days: a is 1;
when the blood sugar changes after three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased within 10% compared with the blood sugar minimum value: a is 1.1;
when the blood glucose changes after three days of the injection subject generally show an ascending trend, and the blood glucose maximum value is increased by more than 10% and within 20% compared with the blood glucose minimum value: a is 1.2;
when the blood glucose changes after three days of the injection subject generally show an ascending trend, and the blood glucose maximum value is increased by more than 20% and within 30% compared with the blood glucose minimum value: a is 1.3;
when the blood glucose changes after three days of the injection subject generally show an ascending trend, and the blood glucose maximum value is increased by more than 30% and within 40% compared with the blood glucose minimum value: a is 1.4;
when the blood glucose changes after three days of the injection subject generally show an ascending trend, and the blood glucose maximum value is increased by more than 40% compared with the blood glucose minimum value: a is 1.5; and is
When the blood sugar changes after three days of the injection subject are generally in a descending trend, and the blood sugar minimum value is reduced within 10% compared with the blood sugar maximum value: a is 0.9;
when the blood sugar changes after three days of the injection subject are generally in a descending trend, and the blood sugar minimum value is reduced by more than 10% and within 20% compared with the blood sugar maximum value: a is 0.8;
when the blood sugar changes after three days of the injection subject are generally in a descending trend, and the blood sugar minimum value is reduced by more than 20% and within 30% compared with the blood sugar maximum value: a is 0.7;
when the blood sugar changes after three days of the injection subject are generally in a descending trend, and the blood sugar minimum value is reduced within 40% compared with the blood sugar maximum value: a is 0.6; and is
Medicine injection amount L before breakfast21=L2×0.6;
Medicine injection L before supper22=L2×0.4。
Further, each detection part includes a working electrode and a reference electrode, the working electrode and the reference electrode being formed of different materials; the peripheral surface of each working electrode is also provided with an electron transfer layer;
the processor is used for analyzing and processing the electric signals between the working electrode and the reference electrode in each detection part, so as to obtain corresponding processing values corresponding to each detection part.
Further, the main control device further comprises: the processor may also accept user settings for the analyte monitoring and automatic drug delivery system. The input device and the processor are electrically connected with the controller.
Furthermore, the main control device also comprises a prompter, and the processor is also used for comparing the processing values corresponding to the detection results of the detection components one by one, and comparing the comparison values obtained after one-to-one comparison with preset threshold values respectively; if the obtained comparison value is larger than the threshold value, the prompter gives an alarm; the prompter is electrically connected with the controller.
Further, the main control device further comprises: the display is used for displaying the calculation result of the processor; the storage stores the calculation result of the processor; the display and the storage are respectively electrically connected with the controller.
Further, the master control device further comprises a transmitter for transmitting the calculation result of the processor and/or the calculation result stored in the storage.
The invention has the beneficial effects that:
the present invention provides an analyte monitoring and automatic drug delivery system comprising: the injection detection device is detachably connected with the temporary storage device or the main regulation and control device; the injection detection device comprises a detection part, injection parts and a substrate, wherein the detection parts are used for detecting an analysis object in an analyte, and the injection parts are used for injecting medicine; the temporary storage device comprises a temporary data storage device and a temporary medicine storage device; the temporary data storage device is used for temporarily storing the detection results of all the detection components; and transmitting the stored detection result to the main control device; the analyte monitoring and automatic drug delivery system provided by the invention is convenient to use, generates pain to patients, and has the advantages of low production cost and small volume.
In order to make the aforementioned and other objects of the present invention comprehensible, preferred embodiments accompanied with figures are described in detail below.
Drawings
The invention will now be described with reference to the accompanying drawings.
FIG. 1a is a schematic perspective view of a primary control device, a temporary storage device, and a filling device of an analyte monitoring and automatic drug delivery system according to an embodiment of the present invention;
FIG. 1b is a schematic perspective view of a temporary storage device and a priming device of an analyte monitoring and automatic drug delivery system according to an embodiment of the present invention;
FIG. 1c is a schematic diagram of another perspective view of a temporary storage and a priming device of an analyte monitoring and automatic drug delivery system according to an embodiment of the present invention;
FIG. 1d is a schematic perspective view of a temporary storage device and a primary control device of an analyte monitoring and automatic drug delivery system provided in an embodiment of the present invention;
FIG. 2a is a schematic perspective view of an injection portion of an analyte monitoring and automatic drug delivery system according to an embodiment of the present invention;
FIG. 2b is a schematic diagram of another embodiment of an injection site of an analyte monitoring and automatic drug delivery system;
FIG. 2c is a schematic diagram of another embodiment of an injection site of an analyte monitoring and automatic drug delivery system;
FIG. 3 is a schematic perspective view of an analyte monitoring and temporary storage device of an automated drug delivery system according to an embodiment of the present invention;
FIG. 4 is a schematic perspective view of a primary control device of an analyte monitoring and automatic drug delivery system according to an embodiment of the present invention;
FIG. 5 is a schematic diagram of an electrical connection configuration of the components of an analyte monitoring and automatic drug delivery system provided by an embodiment of the present invention.
Reference numerals:
1. a filling device; 11. a detection section; 12. a substrate; 13. an injection component; 2. a temporary storage device; 21. a first drug storage component; 22. a piston-type pusher; 3. a main control device; 31. a processor; 32. a controller; 33: a prompter; 34. a display; 35. a reservoir; 36. a transmitter; 37: an input device; 38. a first drug storage component; 39. an injection pump; 311: a processing unit; 312: a comparison unit; 313: a calculation unit; 314: a setting unit; 40. a first connecting member; 41. a second connecting member; 42. a third connecting member; 50. a slide rail; 51. a slider; 52. a card slot; 53. a clamping block; 54. a first adhesive end; 55. and a second adhesive end.
Detailed Description
The embodiments of the present invention are described below with reference to specific embodiments, and other advantages and effects of the present invention will be readily apparent to those skilled in the art from the disclosure of the present specification.
Referring to fig. 1-5, the present invention provides an analyte monitoring and automatic drug delivery system, which is characterized in that the system comprises a detection and injection device 1, a
Referring to fig. 2, the injection device 1 includes at least two
further, the analyte monitoring and automatic drug delivery system provided according to the present invention may be used to determine the concentration of an analyte (e.g., glucose or blood ketones in body fluids) in the human body. For example, continuous or periodic monitoring of analytes in the interstitial fluid of a patient may be used to indicate the glucose level in the patient's bloodstream. Further, in accordance with the analyte monitoring and automatic drug delivery system provided by the present invention, the
Further, the
Further, in the preferred embodiment of the present invention, the
Further, the
Furthermore, it will be apparent to those skilled in the art that for
Further, each of the
Further, in using the analyte monitoring and automatic drug delivery system according to the preferred embodiment of the present invention, the user inserts the
Further, according to the preferred embodiment of the present invention, the
Further, the insertion angle is measured from the skin plane (i.e. the insertion angle should be 90 ° perpendicular to the skin insertion sensor). The insertion angle is typically in the range of 10 ° to 90 °, typically 15 ° to 60 °, more often 30 ° to 45 °. With such a configuration, a patient may experience a significantly reduced pain when using the analyte monitoring and automatic drug delivery system provided by the present invention. Still further, optionally, the
Referring to fig. 1a, fig. 1b and fig. 1c, when the blood glucose analysis needs to be performed outdoors, in order to avoid the
Referring to fig. 4, further, the
Referring to fig. 2, further, the
Referring to fig. 1a, fig. 1b and fig. 1c, further, the injection device 1 is detachably connected to the
Referring to fig. 1a, further, the first connecting element 40 of the present embodiment may be a
Similarly, in fig. 1b, the second connecting member 41 may be a
Similarly, in fig. 1c, the third connecting member 42 may be a
Referring to fig. 5, further, the
Further, there is provided according to another aspect of the present invention an analyte monitoring and automatic drug delivery system, wherein: the processor 31 calculates the total amount of the drug to be injected based on the patient's weight, waist-to-hip ratio, triglyceride level in blood, blood glucose monitor value, and recent trend of blood glucose change.
More particularly, there is provided in accordance with a preferred embodiment of the present invention an analyte monitoring and automatic drug delivery system, wherein: the processor 31 calculates the total injection amount of the drug based on the weight of the patient, the waist-to-hip ratio, the triglyceride content in blood, the blood glucose monitoring mean value before a single day meal, and the trend of blood glucose change over three days. And:
the
wherein:
L1: the total amount of medication injected (u) by the processor 31 before a single daily meal for the patient;
k: body weight (Kg) of the subject;
y: waist-to-hip ratio of the subject;
x: triglyceride (mmol/L) content in blood of the subject of injection, wherein:
triglyceride content below 1.7: x is 1;
a triglyceride content greater than 1.7 and below 2.5: x is 1.1;
a triglyceride content greater than 2.5 and below 5: x is 1.2;
a triglyceride content of greater than 5 and below 10: x is 1.3;
a triglyceride content of greater than 2.5 and less than 5: x is 1.4;
a: mean blood glucose (mmol/L) before a single day meal of the subject;
a: pre-prandial blood glucose trend within three days of the subject, wherein:
when the pre-prandial blood glucose change for the injected subjects was generally within ± 5% of the initial measurement within three days: a is 1;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased within 10% compared with the blood sugar minimum value: a is 1.1;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased by more than 10% and within 20% compared with the blood sugar minimum value: a is 1.2;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased by more than 20% and within 30% compared with the blood sugar minimum value: a is 1.3;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased by more than 30% and within 40% compared with the blood sugar minimum value: a is 1.4;
when the change of blood sugar before meals in three days of the injection subject generally shows an ascending trend, and the blood sugar maximum value is increased by more than 40 percent compared with the blood sugar minimum value: a is 1.5; and is
When the change of blood sugar before meals in three days of the injection subject generally has a descending trend, and the blood sugar minimum value is reduced by 10 percent compared with the blood sugar maximum value: a is 0.9;
when the change of blood sugar before meals in three days of the injection subject is generally in a descending trend, and the blood sugar minimum value is descended by more than 10% and within 20% compared with the blood sugar maximum value: a is 0.8;
when the change of blood sugar before meals in three days of the injection subject is generally in a descending trend, and the blood sugar minimum value is reduced by more than 20% and within 30% compared with the blood sugar maximum value: a is 0.7;
when the change of blood sugar before meals in three days of the injection subject is generally in a descending trend, and the blood sugar minimum value is reduced by less than 40% compared with the blood sugar maximum value: and a is 0.6.
More specifically, the inventor of the present invention performed a verification calculation of the insulin injection amount of 20 typical patients by a large number of multiple sampling, and the specific data table is shown in the following table 1:
TABLE 1
According to the table, the calculation method provided by the invention can accurately calculate the insulin injection amount before meal of the patient according to different body conditions of each patient, so that personalized treatment is performed. More specifically, according to the analyte monitoring and automatic drug delivery system provided by the invention, the total amount L1 of insulin injected before a single-day meal is calculated by the processor 31 according to the weight, waist-hip ratio, triglyceride content in blood, blood glucose monitoring mean value before the single-day meal and change trend of blood glucose before the three-day meal of a patient, and the injection is carried out before the meal by the
Still further, in accordance with another preferred embodiment of the present invention, there is provided an analyte monitoring and automatic drug delivery system, comprising: the processor 31 calculates the total injection amount of the medicine according to the weight, waist-hip ratio, triglyceride content in blood, blood glucose monitoring mean value before single-day meal, blood glucose monitoring mean value after single-day meal and blood glucose change trend in three days of the patient; and is
The processor 31 calculates the total injection amount of the drug according to the following formula:
wherein:
L2: the total amount of drug injected per day (u) by the processor 31;
k: body weight (Kg) of the subject;
y: waist-to-hip ratio of the subject;
x: triglyceride (mmol/L) content in blood of the subject of injection, wherein:
triglyceride content below 1.7: x is 1;
a triglyceride content greater than 1.7 and below 2.5: x is 1.1;
a triglyceride content greater than 2.5 and below 5: x is 1.2;
a triglyceride content of greater than 5 and below 10: x is 1.3;
a triglyceride content of greater than 2.5 and less than 5: x is 1.4;
a: mean blood glucose (mmol/L) before a single day meal of the subject;
a: pre-prandial blood glucose trend within three days of the subject, wherein:
when the pre-prandial blood glucose change for the injected subjects was generally within ± 5% of the initial measurement within three days: a is 1;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased within 10% compared with the blood sugar minimum value: a is 1.1;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased by more than 10% and within 20% compared with the blood sugar minimum value: a is 1.2;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased by more than 20% and within 30% compared with the blood sugar minimum value: a is 1.3;
when the blood sugar changes before meals within three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased by more than 30% and within 40% compared with the blood sugar minimum value: a is 1.4;
when the change of blood sugar before meals in three days of the injection subject generally shows an ascending trend, and the blood sugar maximum value is increased by more than 40 percent compared with the blood sugar minimum value: a is 1.5; and is
When the change of blood sugar before meals in three days of the injection subject generally has a descending trend, and the blood sugar minimum value is reduced by 10 percent compared with the blood sugar maximum value: a is 0.9;
when the change of blood sugar before meals in three days of the injection subject is generally in a descending trend, and the blood sugar minimum value is descended by more than 10% and within 20% compared with the blood sugar maximum value: a is 0.8;
when the change of blood sugar before meals in three days of the injection subject is generally in a descending trend, and the blood sugar minimum value is reduced by more than 20% and within 30% compared with the blood sugar maximum value: a is 0.7;
when the change of blood sugar before meals in three days of the injection subject is generally in a descending trend, and the blood sugar minimum value is reduced by less than 40% compared with the blood sugar maximum value: a is 0.6; and
b: mean blood glucose (mmol/L) after a single day of injection of the subject;
b: a trend of postprandial blood glucose change within three days of the injected subject, wherein:
when the postprandial blood glucose change for the injected subjects was overall within ± 5% of the initial measurement within three days: a is 1;
when the blood sugar changes after three days of the injection subject generally show an ascending trend, and the blood sugar maximum value is increased within 10% compared with the blood sugar minimum value: a is 1.1;
when the blood glucose changes after three days of the injection subject generally show an ascending trend, and the blood glucose maximum value is increased by more than 10% and within 20% compared with the blood glucose minimum value: a is 1.2;
when the blood glucose changes after three days of the injection subject generally show an ascending trend, and the blood glucose maximum value is increased by more than 20% and within 30% compared with the blood glucose minimum value: a is 1.3;
when the blood glucose changes after three days of the injection subject generally show an ascending trend, and the blood glucose maximum value is increased by more than 30% and within 40% compared with the blood glucose minimum value: a is 1.4;
when the blood glucose changes after three days of the injection subject generally show an ascending trend, and the blood glucose maximum value is increased by more than 40% compared with the blood glucose minimum value: a is 1.5; and is
When the blood sugar changes after three days of the injection subject are generally in a descending trend, and the blood sugar minimum value is reduced within 10% compared with the blood sugar maximum value: a is 0.9;
when the blood sugar changes after three days of the injection subject are generally in a descending trend, and the blood sugar minimum value is reduced by more than 10% and within 20% compared with the blood sugar maximum value: a is 0.8;
when the blood sugar changes after three days of the injection subject are generally in a descending trend, and the blood sugar minimum value is reduced by more than 20% and within 30% compared with the blood sugar maximum value: a is 0.7;
when the blood sugar changes after three days of the injection subject are generally in a descending trend, and the blood sugar minimum value is reduced within 40% compared with the blood sugar maximum value: a is 0.6; and is
Injection amount L of medicine before single-day meal21=L2X is 0.6; drug injection L after a single meal22=L2×0.4。
More specifically, the inventors of the present invention performed a verification calculation of the insulin injection amounts of 20 typical patients listed in the above table 1, and the specific data table is shown in the following table 2:
TABLE 2
According to the table, the method for calculating the total insulin injection amount can accurately calculate the total drug (insulin) injection amount per day of the patient according to different physical conditions of each patient. Further, based on the calculated total amount of insulin injected per day of the patient, the amount of insulin injected before the meal of a single day L21 and the amount of insulin injected after the meal of a single day L22 are further calculated. More specifically, according to the method for calculating the total insulin injection amount provided by the invention, aiming at a patient needing to inject insulin twice a day, the medicine injection amount L21 before breakfast is L2 x 0.6; the injection amount of the medicine before breakfast is L22-L2 x 0.4.
More specifically, according to the analyte monitoring and automatic drug delivery system provided by the invention, the total amount of insulin injected per day L2 of each patient is accurately calculated by the processor 31 according to the weight, waist-hip ratio, triglyceride content in blood, blood glucose monitoring mean value before a single day meal, blood glucose monitoring mean value after a single day meal and blood glucose variation trend in three days, so as to obtain the pre-breakfast-drug injection amount L21 and the pre-breakfast-drug injection amount L22 of each patient, and further, the
Further, the processor 31 performs analysis processing on the detection result of each of the
Further, the processor 31 further includes a calculation unit 313 and a comparison unit 312, and the calculation unit 313 performs comparison calculation on the processing value corresponding to each
Further, according to the analyte monitoring and automatic drug delivery system provided by the preferred embodiment of the present invention, the detecting
Further, the analyte monitoring and automatic drug delivery system further comprises a
As described above, the analyte monitoring and automatic drug delivery system according to the present invention can be used to monitor the level of an analyte (e.g., glucose, oxygen, triglyceride or ketone) in a patient over a period of time, and further, at least two
Further, each
Further, according to the analyte monitoring and automatic drug delivery system provided by the present invention, the processor 31 analyzes and processes the electrical signal between the working electrode and the reference electrode in each
Preferably, an analyte monitoring and automatic drug delivery system is provided according to a preferred embodiment of the present invention, wherein: the outer peripheral surface of each working electrode is also provided with an electron transfer layer. More specifically, in the present invention, the peripheral surface of each working electrode is provided with a working surface, which is a portion of the peripheral surface of the working electrode, on which an electron transfer agent is or may be coated, and which is configured to be exposed to an analyte-containing liquid. Further, in the present invention, an "electron transfer agent" is a compound that can carry electrons between an analyte and a working electrode directly or in cooperation with other electron transfer agents, wherein one example of the electron transfer agent is a redox mediator.
In particular, some analytes (e.g., oxygen) may be directly electro-oxidized or electro-reduced at the working electrode. Other analytes, such as glucose and lactose, require the presence of at least one electron transfer agent and/or at least one catalyst to facilitate the electro-oxidation or electro-reduction of the analyte. For analytes (e.g., oxygen) that can be directly electro-oxidized or electro-reduced at the working electrode, a catalyst can also be used. For those analytes that require an electron transfer agent and/or catalyst, each working electrode has an electron transfer agent and/or catalyst formed on or near the working surface of the working electrode. Typically, the working surface is formed on or near only a small portion of the working electrode, often near the tip of the working electrode, and is placed in optimal position to contact the analyte-containing fluid (e.g., a body fluid, a sample fluid, or a carrier fluid). More specifically, the electron transfer agent and/or catalyst may be formed as a solid composition located at the working surface. These components are preferably non-leachable from the working electrode, and more preferably are immobilized on the working electrode. For example, the components may be immobilized on a work surface. Alternatively, the electron transfer agent and/or catalyst may be immobilized within the working surface or between one or more membranes or films deposited onto the working surface, or these components may be immobilized in a polymer or sol-gel matrix. More specifically, the working surface of the working electrode may comprise a catalyst (such as glucose oxidase, lactate oxidase, or laccase) for catalyzing the reaction of the analyte and producing a reactant at the working electrode and/or an electron transfer agent (e.g., an electron transfer agent that facilitates the electro-oxidation of glucose, lactose, or oxygen, respectively) for transferring electrons either indirectly or directly (or both) between the analyte and the working electrode.
Further, according to an analyte monitoring and automatic drug delivery system provided by another aspect of the present invention, the working electrode and the reference electrode in each
Further, the
Referring to fig. 5, further, the
Referring to fig. 5, the
Referring to fig. 5, further, the
Further, in the analyte monitoring and automatic drug delivery system according to the preferred embodiment of the present invention, the comparing unit 312 can further compare the insulin injection amount (i.e., L or L as above) calculated by the calculating unit 313 with a preset drug threshold, and when the insulin injection amount (i.e., insulin injection amount) calculated by the calculating unit 313 is less than the preset drug threshold, a prompt is given to the user through the
Referring to fig. 5, the
Further, it will be apparent to those skilled in the art that the
Referring to fig. 5, further, the
Referring to fig. 5, further, the analyte monitoring and automatic drug delivery system provided by the present invention further includes a
Further, according to the analyte monitoring and automatic drug delivery system provided by the present invention, the
Preferably, according to the analyte monitoring and automatic drug delivery system provided by the present invention: the processor 31, the input device 37, the
Referring to fig. 1, the
In an integrated manner, in the analyte monitoring and automatic drug delivery system provided by this embodiment, in actual operation, the injection device 1 includes a detection component 11, an injection component 13 and a substrate, the injection component 13 is used for injecting a drug, the detection component 11 is disposed on the substrate, the detection component 11 mainly includes a photochemical sensor, the detection component 11 performs sampling detection on the detected analyte, and transmits the detection result to the temporary storage device 2 through an optical signal and a circuit for transient storage; the temporary storage device 2 is connected with the injection device 1 through a circuit, the temporary storage device 2 stores the detection result and then transmits the detection result to the main control device 3, the main control device 3 is connected with the temporary storage device 2 through a circuit, after the main control device 3 receives the detection result, the main control device 3 comprises a processor 31, a controller 32, an input device 37, a prompter 33, a display 34 and a storage 35, the processor 31 comprises a processing unit 311, a comparison unit 312, a calculation unit 313 and a setting unit 314, firstly, the processing unit 311 analyzes and processes the detection result of each detection part 11, and thus a processing value corresponding to the detection result of each detection part 11 is obtained; then, the calculating unit 313 further calculates the detection result of each detection component 11 analyzed and processed by the processing unit 311 to obtain a processing value corresponding to the detection result of each detection component 11; then the comparing unit 312 compares at least one comparison value with a preset threshold value, wherein at least one comparison value is greater than the preset threshold value, and the prompter 33 gives an alarm; the setting unit 314 is then electrically connected to the controller 32, such that various settings of the analyte monitoring device made by the user via the setting unit 314 can be controlled by the control unit for each of the other units; the controller 32 is used for controlling the injection device 1 and the processor 31, the main control device 3 further comprises a prompter 33, if at least one comparison value is compared with a preset threshold value through the comparison unit 312, wherein at least one comparison value is larger than the preset threshold value, the prompter 33 gives an alarm; the main regulation device 3 further comprises: an input device 37 by which a user can input personal information into the automatic drug injection system through the input device 37; the main control device 3 further comprises a display 34, and the display 34 is used for displaying the calculation result of the processor 31; and a storage 35, the storage 35 stores the calculation result of the processor 31; the display 34 and the storage 35 are respectively electrically connected with the controller 32; the regulation and control device also comprises: a transmitter 36, wherein the transmitter 36 is used for transmitting the calculation result of the calculation unit 313 and/or the calculation result stored in the storage 35, if an application software (mobile phone App) adapted to the analyte monitoring and automatic drug delivery system provided by the present invention is installed in the mobile phone of the user, the physical state of the patient can be grasped at any time by pairing with the transmitter 36 (for example, bluetooth pairing, wireless network pairing, etc.), so that the calculation result of the calculation unit 313 and/or the calculation result stored in the storage 35 can be easily obtained on the mobile phone.
Further, it is noted that the preferred embodiment of the present invention is described in the context of a monitoring and drug (insulin) injection system for the treatment of only one disease (diabetes). However, it will be readily apparent to those skilled in the art that the analyte monitoring and automatic drug delivery system provided by the present invention can be used for drug injection for various diseases, for example, for controlling the injection of drugs such as hyperlipidemia and hypertension of patients, which can be arbitrarily selected according to the actual use requirements without any additional creative labor.
The foregoing embodiments are merely illustrative of the principles and utilities of the present invention and are not intended to limit the invention. Any person skilled in the art can modify or change the above-mentioned embodiments without departing from the spirit and scope of the present invention. Accordingly, it is intended that all equivalent modifications or changes which can be made by those skilled in the art without departing from the spirit and technical spirit of the present invention be covered by the claims of the present invention.
- 上一篇:一种医用注射器针头装配设备
- 下一篇:动脉血液采集系统和动脉血液模块